Investor Webinar Briefing

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 13, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medication firm main the event and commercialization of first-in-class units and autologous mobile therapies for pores and skin restoration, invitations shareholders and potential traders to attend its investor webinar and presentation by Dr. Mike Perry, CEO, and Michael Holder, CFO, on September 20, 2022 at 3:30pm (PDT) / September 21, 2022 at 8:30am (AEST).

The webinar will cowl highlights from AVITA Medical’s profitable June 2022 quarter with business income up 39% over the corresponding interval within the prior yr, updates on its developmental pipeline, the corporate’s persevering with objectives for 2022, and conclude with Q&A.

To register for the presentation, please observe this Zoom hyperlink: https://us02web.zoom.us/webinar/register/WN_ZTCqHqzbQrqxhDQwyjHXKQ

Participants are invited to submit questions through the registration web page or in the course of the webinar through the chat perform. A replay will likely be accessible on the AVITA Medical web site, www.avitamedical.com, following the presentation.

ABOUT AVITA MEDICAL, INC.

AVITA Medical is a regenerative medication firm main the event and commercialization of units and autologous mobile therapies for pores and skin restoration. The RECELL® System expertise platform, accepted by the FDA for the therapy of acute thermal burns in each adults and kids, harnesses the regenerative properties of a affected person’s personal pores and skin to create Spray-On Skin™ cells. Delivered on the point-of-care, RECELL permits improved medical outcomes and validated price financial savings. RECELL is the catalyst of a brand new therapy paradigm and AVITA Medical is leveraging its confirmed and differentiated capabilities to develop first-in-class mobile therapies for a number of indications, together with acute traumatic wounds and repigmentation of steady vitiligo lesions. 

AVITA Medical’s first U.S. product, the RECELL System, was accepted by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is accepted for acute partial-thickness thermal burn wounds in sufferers 18 years of age and older or utility together with meshed autografting for acute full-thickness thermal burn wounds in pediatric and grownup sufferers. In February 2022, the FDA reviewed and accepted the PMA complement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed toward offering clinicians a extra environment friendly consumer expertise and simplified workflow. 

The RECELL System is used to arrange Spray-On Skin™ Cells utilizing a small quantity of a affected person’s personal pores and skin, offering a brand new method to deal with extreme burns, whereas considerably lowering the quantity of donor pores and skin required. The RECELL System is designed for use on the level of care alone or together with autografts relying on the depth of the burn harm. Compelling knowledge from randomized, managed medical trials carried out at main U.S. burn facilities and real-world use in additional than 15,000 sufferers globally, reinforce that the RECELL System is a major development over the present commonplace of look after burn sufferers and gives advantages in medical outcomes and value financial savings. Healthcare professionals ought to learn the INSTRUCTIONS FOR USE – RECELL Autologous Cell Harvesting Device (https://recellsystem.com) for a full description of indications to be used and necessary security data together with contraindications, warnings, and precautions. 

In worldwide markets, our merchandise are accepted underneath the RECELL System model to advertise pores and skin therapeutic in a variety of functions together with burns, acute traumatic wounds, vitiligo, and aesthetics. The RECELL System is TGA-registered in Australia, obtained CE-mark approval in Europe and has PMDA approval in Japan. To study extra, go to www.avitamedical.com. 

FOR FURTHER INFORMATION: